-

 As stated in the report of Credit Suisse, the third quarterly revenue of SH PHARMA (02607.HK)  +0.080 (+0.414%)    Short selling $643.69K; Ratio 4.148%   shot up 27.7% to RMB 24.703 billion. Excluding special items, the increasing rate of earnings recorded a year-on-year increase of 13.9%, an acceleration from 5.8% in the first half of the year. It is believed that the annual core earnings will record a double-digit growth. The target price of Shanghai Pharmaceuticals was lifted from $15.04 to $19, which represents 15x of P/E. The rating was maintained at Neutral.
 

Comments

Post a Comment

Popular posts from this blog

-
UCD (01599) plans to raise Rmb600m from A shares issue    Beijing Urban Construction Design & Development Group (UCD) (01599) said it proposes to apply for initial public offering of Renminbi ordinary shares and listing.   The number of public issuance of shares amounts to not more than 149.86 million shares. The issuance price of A shares shall not be lower than Rmb2.91 per share.   The total proceeds raised from the issuance of A shares amount to Rmb600 million, which will be used for upgrading and reconstructing project of the design centre, the national  engineering...
Read more
-
RS Macalline (01528) to issue US$300m guaranteed bonds  Red Star Macalline (01528) said it agreed to issue 3.375% notes due 2022 in the aggregate principal amount of US$300 million.   The company currently intends to use the net proceeds to invest in the development of certain of the Group's portfolio shopping malls, purchase properties for the Group's  operational use, invest in or acquire participants in the home improvement and furnishings business or related businesses, replenish working capital of the Group and apply to general corporate purposes of the Group.   ...
Read more
-
PRADA Deutsche Bank believed and hoped PRADA (01913.HK)    -0.150 (-0.312%)    Short selling $12.87M; Ratio 35.577%   's performance had reached bottom in the third quarter. Looking ahead for the fourth quarter, with the Asian business getting back to normal, relatively low base in the second half of the year and the launch of new products, the company's sales growth may accelerate. Given the expected negative trend of the company's revenue, coupled with deleveraging, the company's EPS forecasts for FY2014-2015 were further cut by 7% and 5% respectively. The Hold rating was maintained and target price was reduced from $55 to $54. 
Read more